Therefore , we assessed the effects of visit-to-visit variability ( VVV ) in HbA1c and fasting glucose on major outcomes in the ADVANCE ( Action in Diabetes and Vascular Disease : Preterax and Diamicron MR Controlled Evaluation ) trial .